The Supreme Court has ruled on whether the company Myriad Genetics can patent two genes connected with breast and ovarian cancer, a case I blogged about in 2010 and again last year. (At least, they've sort of ruled, telling the appeals court that reversed a lower court's ruling invalidating the patent to give the case another look.)

This case, together with the larger question whether some intellectual property claims represent an attempt to patent Nature itself, would make interesting material for a Storify or a conventional essay.